Skip to content
The Nexus
DossierENTITY

CS-101

Coverage of CS-101 in the Nexus archive.

Earliest in view: Apr 8 · 00:00 UTCMost recent: Apr 8 · 00:00 UTC
Co-mentioned in this coverage
Natureorganization1β-thalassaemiadisease1base editingtechnology1
Recent coverage
  • HEALTHApr 8 · 00:00 UTCNATURE NEWS
    Clinical application of base editing for treating β-thalassaemia

    A phase 1 clinical trial using CS-101, CD34+ cells modified with a transformer base editor, showed early and sustained transfusion independence in β-thalassaemia patients. The treatment reactivates fetal hemoglobin production, offering a potential breakthrough in genetic disorder therapy.